Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study

Authors: Rose ZW Ting, Xilin Yang, Linda WL Yu, Andrea OY Luk, Alice PS Kong, Peter CY Tong, Wing-Yee So, Juliana CN Chan, Ronald CW Ma

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

Dyslipidaemia is an important but modifiable risk factor of cardiovascular disease (CVD) in type 2 diabetes. Yet, the effectiveness of lipid regulating drugs in Asians is lacking. We examined the effects of lipid control and treatment with lipid regulating drugs on new onset of CVD in Chinese type 2 diabetic patients.

Methods

In this prospective cohort consisting of 4521 type 2 diabetic patients without history of CVD and naïve for lipid regulating treatment recruited consecutively from 1996 to 2005, 371 developed CVD after a median follow-up of 4.9 years. We used Cox proportional hazard regression to obtain the hazard ratios (HR) of lipids and use of lipid regulating drugs for risk of CVD.

Results

The multivariate-adjusted HR (95% confidence interval) of CVD in patients with high LDL-cholesterol (≥ 3.0 mmol/L) was 1.36 (1.08 - 1.71), compared with lower values. Using the whole range value of HDL-cholesterol, the risk of CVD was reduced by 41% with every 1 mmol/L increase in HDL-cholesterol. Plasma triglyceride did not predict CVD. Statins use was associated with lower CVD risk [HR = 0.66 (0.50 - 0.88)]. In sub-cohort analysis, statins use was associated with a HR of 0.60 (0.44 - 0.82) in patients with high LDL-cholesterol (≥ 3.0 mmol/L) and 0.49 (0.28 - 0.88) in patients with low HDL-cholesterol. In patients with LDL-cholesterol < 3.0 mmol/L, use of fibrate was associated with HR of 0.34 (0.12 - 1.00). Only statins were effective in reducing incident CVD in patients with metabolic syndrome [(HR = 0.58(0.42--0.80)].

Conclusions

In Chinese type 2 diabetic patients, high LDL-cholesterol and low HDL-cholesterol predicted incident CVD. Overall, patients treated with statins had 40-50% risk reduction in CVD compared to non-users.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009, 301 (20): 2129-2140. 10.1001/jama.2009.726.CrossRefPubMed Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009, 301 (20): 2129-2140. 10.1001/jama.2009.726.CrossRefPubMed
2.
go back to reference Executive summary: Standards of medical care in diabetes--2010. Diabetes Care. 2010, 33 (Suppl 1): S4-10. Executive summary: Standards of medical care in diabetes--2010. Diabetes Care. 2010, 33 (Suppl 1): S4-10.
3.
go back to reference Kong AP, Yang X, Ko GT, So WY, Chan WB, Ma RC, Ng VW, Chow CC, Cockram CS, Tong PC, et al: Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care. 2007, 30 (4): 953-959. 10.2337/dc06-2443.CrossRefPubMed Kong AP, Yang X, Ko GT, So WY, Chan WB, Ma RC, Ng VW, Chow CC, Cockram CS, Tong PC, et al: Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care. 2007, 30 (4): 953-959. 10.2337/dc06-2443.CrossRefPubMed
4.
go back to reference Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, Ilkova H, Ramachandran A, Aschner P: Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009, 32 (2): 227-233. 10.2337/dc08-0435.PubMedCentralCrossRefPubMed Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, Ilkova H, Ramachandran A, Aschner P: Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009, 32 (2): 227-233. 10.2337/dc08-0435.PubMedCentralCrossRefPubMed
5.
go back to reference Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M: Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Diabet Med. 1993, 10 (4): 371-377. 10.1111/j.1464-5491.1993.tb00083.x.CrossRefPubMed Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M: Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Diabet Med. 1993, 10 (4): 371-377. 10.1111/j.1464-5491.1993.tb00083.x.CrossRefPubMed
6.
go back to reference Harrell F: Regression Modelling Strategies with applications to Linear Models, Logistic Regression, and Survival Analysis. 2001, New York: Springer Harrell F: Regression Modelling Strategies with applications to Linear Models, Logistic Regression, and Survival Analysis. 2001, New York: Springer
7.
go back to reference Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC, Tong PC, Chan JC: Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ. 2008, 179 (5): 427-437.PubMedCentralCrossRefPubMed Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC, Tong PC, Chan JC: Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ. 2008, 179 (5): 427-437.PubMedCentralCrossRefPubMed
8.
go back to reference Yang X, Ko GT, So WY, Ma RC, Kong AP, Lam CW, Ho CS, Chow CC, Tong PC, Chan JC: Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry. Diabetes Care. 2008, 31 (12): 2294-2300. 10.2337/dc08-1079.PubMedCentralCrossRefPubMed Yang X, Ko GT, So WY, Ma RC, Kong AP, Lam CW, Ho CS, Chow CC, Tong PC, Chan JC: Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry. Diabetes Care. 2008, 31 (12): 2294-2300. 10.2337/dc08-1079.PubMedCentralCrossRefPubMed
9.
go back to reference Joffe MM, Rosenbaum PR: Invited commentary: propensity scores. Am J Epidemiol. 1999, 150 (4): 327-333.CrossRefPubMed Joffe MM, Rosenbaum PR: Invited commentary: propensity scores. Am J Epidemiol. 1999, 150 (4): 327-333.CrossRefPubMed
10.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120 (16): 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120 (16): 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed
11.
go back to reference Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993, 16 (2): 434-444. 10.2337/diacare.16.2.434.CrossRefPubMed Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993, 16 (2): 434-444. 10.2337/diacare.16.2.434.CrossRefPubMed
12.
go back to reference Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004, 164 (13): 1422-1426. 10.1001/archinte.164.13.1422.CrossRefPubMed Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004, 164 (13): 1422-1426. 10.1001/archinte.164.13.1422.CrossRefPubMed
13.
go back to reference Kannel WB: Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985, 110 (5): 1100-1107. 10.1016/0002-8703(85)90224-8.CrossRefPubMed Kannel WB: Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985, 110 (5): 1100-1107. 10.1016/0002-8703(85)90224-8.CrossRefPubMed
14.
go back to reference Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009, 5 (3): 150-159. 10.1038/ncpendmet1066.CrossRefPubMed Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009, 5 (3): 150-159. 10.1038/ncpendmet1066.CrossRefPubMed
15.
go back to reference Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371 (9607): 117-125. 10.1016/S0140-6736(08)60104-X.CrossRefPubMed Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371 (9607): 117-125. 10.1016/S0140-6736(08)60104-X.CrossRefPubMed
16.
go back to reference Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.
17.
go back to reference Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society British Hyperlipidaemia Association British Hypertension Society British Diabetic Association. BMJ. 2000, 320 (7236): 705-708. 10.1136/bmj.320.7236.705. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society British Hyperlipidaemia Association British Hypertension Society British Diabetic Association. BMJ. 2000, 320 (7236): 705-708. 10.1136/bmj.320.7236.705.
18.
go back to reference Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977, 62 (5): 707-714. 10.1016/0002-9343(77)90874-9.CrossRefPubMed Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977, 62 (5): 707-714. 10.1016/0002-9343(77)90874-9.CrossRefPubMed
19.
go back to reference Barzi F, Patel A, Woodward M, Lawes CM, Ohkubo T, Gu D, Lam TH, Ueshima H: A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. Ann Epidemiol. 2005, 15 (5): 405-413. 10.1016/j.annepidem.2005.01.005.CrossRefPubMed Barzi F, Patel A, Woodward M, Lawes CM, Ohkubo T, Gu D, Lam TH, Ueshima H: A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. Ann Epidemiol. 2005, 15 (5): 405-413. 10.1016/j.annepidem.2005.01.005.CrossRefPubMed
20.
go back to reference Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007, 115 (4): 450-458. 10.1161/CIRCULATIONAHA.106.637793.CrossRefPubMed Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007, 115 (4): 450-458. 10.1161/CIRCULATIONAHA.106.637793.CrossRefPubMed
21.
go back to reference Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997, 96 (8): 2520-2525.CrossRefPubMed Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997, 96 (8): 2520-2525.CrossRefPubMed
22.
go back to reference Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008, 300 (18): 2142-2152. 10.1001/jama.2008.621.CrossRefPubMed Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008, 300 (18): 2142-2152. 10.1001/jama.2008.621.CrossRefPubMed
23.
go back to reference Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, et al: Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009, 302 (18): 1993-2000. 10.1001/jama.2009.1619.CrossRefPubMed Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, et al: Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009, 302 (18): 1993-2000. 10.1001/jama.2009.1619.CrossRefPubMed
24.
go back to reference Amarenco P, Labreuche J: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009, 8 (5): 453-463. 10.1016/S1474-4422(09)70058-4.CrossRefPubMed Amarenco P, Labreuche J: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009, 8 (5): 453-463. 10.1016/S1474-4422(09)70058-4.CrossRefPubMed
25.
go back to reference Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, et al: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009, 338: b2376-10.1136/bmj.b2376.PubMedCentralCrossRefPubMed Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, et al: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009, 338: b2376-10.1136/bmj.b2376.PubMedCentralCrossRefPubMed
26.
go back to reference Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359 (21): 2195-2207. 10.1056/NEJMoa0807646.CrossRefPubMed Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359 (21): 2195-2207. 10.1056/NEJMoa0807646.CrossRefPubMed
27.
go back to reference Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009, 32 (3): 493-498. 10.2337/dc08-1543.PubMedCentralCrossRefPubMed Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009, 32 (3): 493-498. 10.2337/dc08-1543.PubMedCentralCrossRefPubMed
28.
go back to reference Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010, 362 (17): 1563-1574. 10.1056/NEJMoa1001282.CrossRefPubMed Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010, 362 (17): 1563-1574. 10.1056/NEJMoa1001282.CrossRefPubMed
29.
go back to reference Chen Z, Yin Q, Ma G, Qian Q: KCNQ1 gene polymorphisms are associated with lipid parameters in a Chinese Han population. Cardiovasc Diabetol. 2010, 9: 35-10.1186/1475-2840-9-35.PubMedCentralCrossRefPubMed Chen Z, Yin Q, Ma G, Qian Q: KCNQ1 gene polymorphisms are associated with lipid parameters in a Chinese Han population. Cardiovasc Diabetol. 2010, 9: 35-10.1186/1475-2840-9-35.PubMedCentralCrossRefPubMed
30.
go back to reference Wan J, Xiong S, Chao S, Xiao J, Ma Y, Wang J, Roy S: PPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol. 2010, 9: 13-10.1186/1475-2840-9-13.PubMedCentralCrossRefPubMed Wan J, Xiong S, Chao S, Xiao J, Ma Y, Wang J, Roy S: PPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol. 2010, 9: 13-10.1186/1475-2840-9-13.PubMedCentralCrossRefPubMed
31.
go back to reference Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003, 158 (9): 915-920. 10.1093/aje/kwg231.CrossRefPubMed Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003, 158 (9): 915-920. 10.1093/aje/kwg231.CrossRefPubMed
32.
go back to reference Yang X, Ma RC, Chan JC: Response to comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes; 59:1254-1260. Diabetes. 2010, 59: e19-e22. 10.2337/db10-0859.CrossRef Yang X, Ma RC, Chan JC: Response to comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes; 59:1254-1260. Diabetes. 2010, 59: e19-e22. 10.2337/db10-0859.CrossRef
33.
go back to reference Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH: Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. Am J Health Syst Pharm. 2005, 62 (4): 411-415.PubMed Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH: Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. Am J Health Syst Pharm. 2005, 62 (4): 411-415.PubMed
34.
go back to reference Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH: Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol. 2004, 58 (5): 528-535. 10.1111/j.1365-2125.2004.02202.x.PubMedCentralCrossRefPubMed Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH: Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol. 2004, 58 (5): 528-535. 10.1111/j.1365-2125.2004.02202.x.PubMedCentralCrossRefPubMed
35.
go back to reference Lehman R, Krumholz HM: Tight control of blood glucose in long standing type 2 diabetes. BMJ. 2009, 338: b800-10.1136/bmj.b800.CrossRefPubMed Lehman R, Krumholz HM: Tight control of blood glucose in long standing type 2 diabetes. BMJ. 2009, 338: b800-10.1136/bmj.b800.CrossRefPubMed
Metadata
Title
Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study
Authors
Rose ZW Ting
Xilin Yang
Linda WL Yu
Andrea OY Luk
Alice PS Kong
Peter CY Tong
Wing-Yee So
Juliana CN Chan
Ronald CW Ma
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-77

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.